Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.

Primary tabs

field_vote: 
Average: 7 (1 vote)
Other Key Words:: 
References: 
Therapeutic intervention: 
Therapeutic Substance(s): 

J Clin Psychopharmacol. 2010 Aug;30(4):476-8.

Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.

Mannelli P, Peindl K, Patkar AA, Wu LT, Pae CU, Gorelick DA.

Introduction

Although the influence of cannabis use on the abuse of other drugs or their treatment may vary,1,2 the increasing severity of cannabis use and its resistance to treatment warrant looking for more effective intervention strategies.3 Multiple interactions exist between opioid and cannabinoid systems; opioid antagonist medications such as naltrexone (NTX) at low doses have been proposed to reduce cannabis reinforcement and consumption.4 In a randomized, double-blind, placebo-controlled clinical trial, we found that daily addition to methadone taper of very-low-dose NTX (VLNTX, 0.125 mg/d, 0.250 mg/d) was associated with attenuated opioid withdrawal during inpatient detoxification and with reduced use of opioids and cannabis, measured by urine drug testing and self-report the day after discharge (D1) and 1 week later (D7).5 The study was carried out in accordance with the Declaration of Helsinki and was approved by the institutional review boards of Duke University, Durham, NC, and Thomas Jefferson University, Philadelphia, Pa.